Partners

Physiomics plc works with partners from both small and large pharmaceutical and biotechnology companies. These include Cyclacel Pharmaceutical, Eli Lilly and ValiRx.

Our technology has conferred many benefits to our partners:

	Our apoptosis model technology has supported both “no-go” and “go” decisions for therapeutic targets. George Morris, Chief Development Officer of ValiRx, said: "Physiomics service and technology is absolutely superb, we (ValiRx) have just had some work carried out and it has saved us very significant amounts of development money and time. This is the first time the research has been done this way....."
We are developing our technology with both industrial and academic partners across the European Union:
	As part of the TEMPO project we are developing combined pharmacokinetic-pharmacodynamic models of cancer processes in order to determine optimal chronotherapeutic scheduling for cell cycle inhibitors. The aim is that this will support a clinical trial in the future.
We are also working with other industrial partners to develop and enhance our technological capability:
We use the powerful Bayer Technology Services software, PK-Sim™ and MoBi™ in order to accurately simulate drug pharmacokinetics.
	We are currently working with the Institute of Life Science at Swansea University (ILS) running simulations on their "Blue C" IBM high-performance computer. This allows our simulations to be more complex, more accurate and therefore more useful. We also set up a research collaboration with a team of scientists at the ILS as part of our continual technology development.

If you are interested in knowing more about Physiomics and how we might deliver benefit to your research effort, please contact us.

Back to the top